Predicting Flare Risk After Stopping Adalimumab in RA Predicting Flare Risk After Stopping Adalimumab in RA
A new study examines the question of whether adalimumab trough and antidrug antibody levels predict flare among rheumatoid arthritis patients who have stopped adalimumab.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Why Does Medicine Cost So Much? Here ’s How Drug Prices Are Set
From 2007 to 2016, Mylan raised the list price of its EpiPen about 500%, from just under $100 to more than $600. From 2002 to 2013, insulin prices more than tripled. From 2012 to 2019, the average price of AbbVie’s rheumatoid-arthritis drug Humira climbed from $19,000 a year to $60,000 a year—and that’s after rebates. These are dramatic examples of a systemwide problem: prices for brand-name drugs are rising at a rate that far outstrips inflation. What’s behind these rapid price hikes? It’s a simple question with a complicated answer that involves three central entities: drug manufacturers, ph...
Source: TIME: Health - April 9, 2019 Category: Consumer Health News Authors: Laura Entis Tags: Uncategorized medicine Source Type: news

Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

AbbVie ’s next potential blockbuster wins approval in Japan
With AbbVie ’s top-selling Humira headed for the patent cliff, the company is gaining momentum for a global rollout of its next potential blockbuster. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 27, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Is it safe to take Humira and alcohol together?
Humira is a biologic medication that treats inflammatory conditions. In this article, we look at the safety and risks associated with taking Humira and drinking alcohol. We also discuss other Humira side effects and interactions. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 26, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news

Challenging Goliath – How Underdogs Stand A Fighting Chance
We all love an underdog story. Who isn ’t moved by the passion, grit, and determination that drives an outsider to overcome near-impossible odds? Rudy, Rocky, Million Dollar Baby, Miracle – Hollywood has captured our hearts while cashing in on this timeless trope. When it comes to the biopharmaceutical arena, however, we sometimes lo ok down upon the upstart rather than embrace its potential.Smaller companies and products often face the Herculean challenge of going up against the super-power, mega-sized pharma companies. Smaller budgets, operational teams, and fewer sales reps are viewed as insurmountable odds....
Source: EyeForPharma - March 24, 2019 Category: Pharmaceuticals Authors: Francesco Lucarelli Source Type: news

Class action lawsuit accuses AbbVie of creating ‘patent thicket’ for Humira
AbbVie is once again facing pressure for its alleged attempts to protect its blockbuster medication, Humira, from generics competition. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 20, 2019 Category: Pharmaceuticals Source Type: news

Cancer Drugs Dominate Top 10 Best-Selling Drugs in 2018 Cancer Drugs Dominate Top 10 Best-Selling Drugs in 2018
But Humira is the top seller in US 2 years running, while two immune checkpoint inhibitors break into the top 10.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Medical News Today: Stelara vs. Humira: What's the difference?
Stelara and Humira are two biologics that help treat immune conditions, such as psoriatic arthritis and Crohn ’s disease. In this article, we look at the similarities and differences in their effects, benefits, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news

Entyvio Tops Humira in Head-to-Head UC trial
(MedPage Today) -- More vedolizumab patients achieved clinical remission, mucosal healing in VARSITY trial (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 13, 2019 Category: Primary Care Source Type: news

Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400 participants to be enrolled in Phase III study at 30 sites ... Biopharmaceuticals, Generics, Dermatology Alvotech, HUMIRA, biosimilar, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2019 Category: Pharmaceuticals Source Type: news

Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress
Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 26, 2019 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NYSE:ABT NYSE:ABBV NYSE:JNJ NYSE:BMY NYSE:PFE Source Type: news

The world's best-selling drug costs SIX times more in the US than the UK
Drug maker Abbvie made over $18 billion on it's arthritis drug, Humira, in 2017. It has kept a monopoly on the drug by making tiny changes to the formula, which costs over $5,600 in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2019 Category: Consumer Health News Source Type: news

EU Panel Recommends Humira Biosimilars Idacio, Kromeya EU Panel Recommends Humira Biosimilars Idacio, Kromeya
The EMA's Committee for Medicinal Products for Human Use has recommended marketing authorization for two biosimilars that are highly similar to Humira (adalimumab, AbbVie).FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2019 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Longitudinal TNF Levels Mainly Stable With Adalimumab in RA
FRIDAY, Feb. 1, 2019 -- For patients with rheumatoid arthritis (RA), longitudinal tumor necrosis factor (TNF) concentrations are mainly stable during adalimumab treatment, although early low TNF is strongly linked to nonresponse to treatment,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2019 Category: Pharmaceuticals Source Type: news

GI Case Quiz: Ileocolonic Anastomosis a Success, New Symptoms Arise
What might cause severe abdominal bloating& diarrhea 3 years after ileocolonic resection and adalimumab/methotrexate treatment?   (Source: ConsultantLive)
Source: ConsultantLive - January 30, 2019 Category: Internal Medicine Authors: Ted W. James, MD Tags: Gastrointestinal Disorders Source Type: news

FDA approves J & J ’s Tremfya self-injection pen for psoriasis
FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Get the full story on our sister site, Drug Delivery Business. The post FDA approves J&J’s Tremfya self-injection pen for psoriasis appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Drug-Device Combinations Food & Drug Administration (FDA) News Well AbbVie Janssen Pharmaceuticals johnsonandjohnson Source Type: news

Drug Companies Greet 2019 With U.S. Price Hikes Drug Companies Greet 2019 With U.S. Price Hikes
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 17, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Drug companies greet 2019 with U.S. price hikes
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Lilly drug shown to be more effective than Humira in late-stage study
Eli Lilly Co. released results from a study this week showing that its drug, Taltz, was better at treating psoriatic arthritis than Humira. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 17, 2018 Category: Pharmaceuticals Source Type: news

Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
INDIANAPOLIS, Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the ef... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis, SPIRIT-H2H trial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 17, 2018 Category: Pharmaceuticals Source Type: news

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - December 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

The Little-Known Way Pharma Companies Hook People On Their Costly Drugs
Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price. “Nothing in the world gives me more anxiety than just getting my medication,” Burgess said. “There’s nothing you can do but beg.” Panicked, Burgess had called Amgen and pleaded for help. The drugmaker sent him the check after he provided a credit card statement and an explanat...
Source: TIME: Health - December 12, 2018 Category: Consumer Health News Authors: Sarah Jane Tribble / Kaiser Health News Tags: Uncategorized Drugs Source Type: news

Pfizer reaches a global agreement with AbbVie
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. (Source: World Pharma News)
Source: World Pharma News - December 4, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Adalimumab biosimilar will save drug costs for NHS England
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
NORTH CHICAGO, Ill., Nov. 30, 2018 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant... Biopharmaceuticals, Generics, Licensing AbbVie, Pfizer, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2018 Category: Pharmaceuticals Source Type: news

NHS ditches its most expensive drug used by 46,000 arthritis sufferers
Health  bosses have signed a deal to save £300million a year by using cheaper versions of a costly arthritis drug. More than 46,000 English patients take adalimumab, which had been £400million a year. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2018 Category: Consumer Health News Source Type: news

NHS ditches its most expensive drug used by 46,000 arthritis sufferers in bid to save £300million
Health  bosses have signed a deal to save £300million a year by using cheaper versions of a costly arthritis drug. More than 46,000 English patients take adalimumab, which had been £400million a year. (Source: the Mail online | Health)
Source: the Mail online | Health - November 26, 2018 Category: Consumer Health News Source Type: news

NHS set to save £300 million on NHS’s highest drug spend
Biosimilar versions of adalimumab to be introduced Related items fromOnMedica Cancer Drugs Fund ‘wasteful and harmful’ The medicine price debate Drug prices may rise for NHS after Brexit NHS saves £324m by switching to cheaper medicines (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 26, 2018 Category: UK Health Source Type: news

Paradoxical Development of Panuveitis and Granulomatous Interstitial Lung Disease Associated with Adalimumab Therapy for Psoriasis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Medical News Today: Differences between Enbrel and Humira
Enbrel and Humira are medications that doctors prescribe to treat rheumatoid arthritis and other conditions. Both help lower inflammation in the joints and are similar, regarding their available forms, storage, and costs. Learn more about Enbrel and Humira, and which might be the most appropriate, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2018 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

FDA approves Novartis' copy of AbbVie bestseller Humira
The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - October 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira
Holzkirchen, Germany, October 31, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 31, 2018 Category: Drugs & Pharmacology Source Type: news

A Humira Prescription Costs $38,000 A Year Because Our Patent System Is Being Abused
America's seniors deserve better. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - October 28, 2018 Category: Science Source Type: news

New JAK1 Agent Beats Humira in Rheumatoid Arthritis
(MedPage Today) -- Thrombotic events balanced between upadacitinib, adalimumab, and placebo (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 22, 2018 Category: Rheumatology Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates Fresenius Kabi Acknowledges Validity of AbbVie's Intellectual Property ... Biopharmaceuticals, Litigation, Licensing AbbVie, Fresenius Kabi, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2018 Category: Pharmaceuticals Source Type: news

AbbVie settles Humira biosimilar dispute with Fresenius Kabi
U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen launches AMGEVITATM (Biosimilar Adalimumab) In markets across Europe
Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of (Source: World Pharma News)
Source: World Pharma News - October 17, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU
Rival versions of the world ’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biosimilars set to benefit patients and the NHS
Today marks the European patent expiry for the biologic Adalimumab (Humira), which is prescribed in hospitals for conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Adalimumab (Humira)
Title: Adalimumab (Humira)Category: MedicationsCreated: 10/16/2018 12:00:00 AMLast Editorial Review: 10/16/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidenc...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

‘Patients Deserve to Know’: Trump Administration Wants Drug Commercials to Show Prices
TRENTON, N.J. — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials. The drug industry’s main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they’ll start doing that next spring. Health and Human Services Secretary Alex Azar unveiled a proposal that would apply to all brand-name drugs covered by the Medicare and Medicaid programs, which is most medicines. “Patients deserve to know what a given drug could cost when they’re being told about th...
Source: TIME: Health - October 16, 2018 Category: Consumer Health News Authors: LINDA A. JOHNSON / AP Tags: Uncategorized Healthcare onetime Source Type: news

Rivals line up to take on world’s best-selling drug
As the European patent on AbbVie’s Humira expires, biosimilars are ready to target $20bn market (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 14, 2018 Category: Pharmaceuticals Source Type: news

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab). (Source: World Pharma News)
Source: World Pharma News - October 12, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Abbvie settles Humira patent disputes with Novartis unit
Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news